DPP4 and lung adenocarcinoma: None were treated with dipeptidyl peptidase-4 inhibitor (DPP4i).The seventh patient in the series had BP secondary to pembrolizumab treatment due to lung adenocarcinoma, which was crucial and could not be ceased.